Status:
UNKNOWN
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Ovarian Cancer
Neoadjuvant Chemotherapy
Eligibility:
FEMALE
18-75 years
Brief Summary
A validated prognostic index for the outcome of advanced high-grade serous ovarian cancer (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT) is still lacking. To address this need, we develop...
Detailed Description
1. The clinicopathological data of patients newly diagnosed with high-grade serous ovarian cancer in Sun Yat-sen Memorial Hospital were collected and screened. 2. Statistical analysis of hematological...
Eligibility Criteria
Inclusion
- confirmed diagnosis of HGSOC by two experienced pathologists;
- clinical stage III-IV according to the 2018 International Federation of Gynecology and Obstetrics (FIGO) guideline;
- Eastern Cooperative Oncology Group (ECGO) performance status of 0 to 1;
- no prior anti-cancer therapy;
- received ≥ 3 cycles of platinum-based NACT followed by IDS;
- complete pretreatment blood test results and clinical and imaging data.
Exclusion
- other pathological types;
- without NACT or IDS;
- incomplete pretreatment data;
- lost to follow-up.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
465 Patients enrolled
Trial Details
Trial ID
NCT06120309
Start Date
November 1 2023
End Date
December 31 2024
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 520120